Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370214 · ClinicalTrials.gov registry record
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 3,515
- Enrollment target
NCT00370214 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 3,515 participants.
The verdict
NCT00370214 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 3,515 participants
- Enrollment target
Study Summary
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating institutions will be enrolled. Participating patients will be followed for a minimum of five years from the time of enrollment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,515 participants |
| Start Date | 2006-03 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00370214
The ClinicalTrials.gov registry entry for NCT00370214 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,515 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00370214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00370214 about?
NCT00370214 is a clinical study titled "REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management". The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients. All consecutive consenting patients diagnosed with WHO Group I PAH according to specific hemodynamic criteria at participating insti...
What is the current status of trial NCT00370214?
This trial is currently completed. The enrollment target is 3,515 participants. The study started on 2006-03. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT00370214?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.